• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Incannex Healthcare Inc.

    11/14/25 6:08:48 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IXHL alert in real time by email
    S-8 1 ea0265434-s8_incannex.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on November 14, 2025

     

    REGISTRATION NO. 333 -         

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    under the

    SECURITIES ACT OF 1933

     

    Incannex Healthcare Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   93-2403210
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    Rialto South Tower

    Level 23, 525 Collins Street

    Melbourne VIC 3008
    Australia

    (Address of Principal Executive Offices)(Zip Code)

     

    Incannex Healthcare Inc. 2023 Equity Incentive Plan

    (Full titles of the plan(s))

     

    Joel Latham

    Chief Executive Officer and President

    Incannex Healthcare Inc.

    Rialto South Tower

    Level 23, 525 Collins Street

    Melbourne VIC 3008
    Australia

    +61 409 840 786

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Scott M. Stanton, Esq.

    Melanie Ruthrauff Levy, Esq.

    Jason Miller, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC

    3580 Carmel Mountain Road, Suite 300

    San Diego, CA 92030

    858-314-1873

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐   Accelerated filer ☐  
    Non-accelerated filer ☒   Smaller reporting company ☒  
          Emerging growth company ☒  

     

    If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed with the U.S. Securities and Exchange Commission (the “SEC”) for the purpose of registering an additional 69,541,101 shares of common stock of Incannex Healthcare Inc. (the “Registrant”) issuable, or which may become issuable, under the Incannex Healthcare Inc. 2023 Equity Incentive Plan as amended by that certain amendment dated May 27, 2025 (as amended, the “2023 Plan”)  pursuant to the “evergreen” provision of such plan.

     

    Pursuant to General Instruction E on Form S-8, the contents of the prior registration statements on Form S-8, File Nos. 333-276172 and 333-287786, previously filed with respect to the 2023 Plan, are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the SEC are incorporated herein by reference:

     

    (a)The Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025 filed with the SEC on September 29, 2025;

     

    (b)The Registrant’s Current Reports on Form 8-K filed with the SEC on July 24, 2025, July 25, 2025, July 30, 2025, July 31, 2025, August 8, 2025, August 22, 2025, August 26, 2025; October 22, 2025, October 22, 2025, October 30, 2025; and

     

    (c)the description of the common stock contained in Exhibit 4.1 of the Registrant’s Annual Report on Form 10-K filed with the SEC on September 29, 2025, including any amendments or reports filed for the purpose of updating such description.

     

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Under no circumstances shall any information furnished under Item 2.02 or 7.01 of Current Report on Form 8-K be deemed incorporated herein by reference unless such Current Report on Form 8-K expressly provides to the contrary.

     

    II-1

     

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
         
    3.1   Certificate of Amendment to Amended and Restated Certificate of Incorporation of Incannex Healthcare Inc., dated May 27, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on May 28, 2025).
         
    3.2   Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on July 31, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 29, 2023)
         
    3.3   Amended and Restated Bylaws, dated November 20, 2023 (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the SEC on November 29, 2023)
         
    5.1*   Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
         
    23.1*   Consent of Grant Thornton
         
    23.2*   Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (contained in Exhibit 5.1 hereto)
         
    24.1*   Power of Attorney (included on signature page)
         
    99.1   Amendment No. 1 to Incannex Healthcare Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 of the Company’s Registration Statement on Form S-8 filed with the SEC on June 4, 2025)
         
    99.2   Incannex Healthcare Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on November 29, 2023)
         
    107*   Filing Fee Table

     

    *Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Melbourne, Victoria, Australia on the 14th day of November, 2025.

     

      INCANNEX HEALTHCARE INC.
         
      By: /s/ Joel Latham
      Name:  Joel Latham
      Title: Chief Executive Officer, President and Director

     

    POWER OF ATTORNEY AND SIGNATURES

     

    We, the undersigned officers and directors of Incannex Healthcare Inc., hereby severally constitute and appoint Joel Latham and Joseph Swan, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Person   Capacity   Date
             
    /s/ Joel Latham   Chief Executive Officer, President and Director   November 14, 2025
    Joel Latham   (Principal Executive Officer)    
             
    /s/ Joseph Swan   Chief Financial Officer   November 14, 2025
    Joseph Swan   (Principal Financial and Accounting Officer)    
             
    /s/ Troy Valentine   Chairman   November 14, 2025
    Troy Valentine        
             
    /s/ Peter Widdows   Director   November 14, 2025
    Peter Widdows        
             
    /s/ George Anastassov   Director   November 14, 2025
    George Anastassov        
             
    /s/ Robert Clark   Director   November 14, 2025
    Robert Clark        

     

    II-3

     

    Get the next $IXHL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IXHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IXHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Valentine Troy was granted 11,302,608 shares, increasing direct ownership by 1,616% to 12,001,858 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:18:24 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Clark Robert was granted 1,686,956 shares, increasing direct ownership by 1,687% to 1,786,956 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:17:03 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Widdows Peter was granted 1,686,956 shares, increasing direct ownership by 623% to 1,957,803 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:15:28 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    SEC Filings

    View All

    SEC Form 10-Q filed by Incannex Healthcare Inc.

    10-Q - Incannex Healthcare Inc. (0001873875) (Filer)

    11/14/25 6:24:48 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Incannex Healthcare Inc.

    S-8 - Incannex Healthcare Inc. (0001873875) (Filer)

    11/14/25 6:08:48 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    10/30/25 8:00:49 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus

    MELBOURNE, Australia and NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL)("Incannex" or the "Company"), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, provides a shareholder update highlighting recent progress across its clinical and corporate initiatives and outlining key priorities for the remainder of 2025. Recent Highlights IHL-42X (OSA) Phase 2 – Statistically significant efficacy, outstanding patient-reported outcomes, and strong safety profile – Incannex reported Phase 2 data for IHL-42X demonstrating statistically significant and clinically meaningful reductions in Apnea-Hyp

    10/30/25 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    MELBOURNE, Australia and NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). Incannex now has until April 20, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least US$1.00 per share for a minimum of ten consecutive business days (which may be extended to twenty consec

    10/22/25 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

    MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted psychotherapy treatment for Generalised Anxiety Disorder (GAD). The results confirm statistically significant and clinically meaningful improvements across every key endpoint assessed in the study, reinforcing PSX-001's potential as a best-in-class therapy for patients with moderate to severe GAD. Trial Design OverviewThe randomized, double-blind, placebo-controlled Phase 2 study enrolled 73 adult participants diagnosed with moderate t

    8/26/25 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Leadership Updates

    Live Leadership Updates

    View All

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

    NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:"We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Advisory Board. Her leadership across neurology, psychiatry, and public health, combined with a distinguished track record in sleep medicine, brings tremendous value to our obstructive sleep apnea prog

    7/25/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

    NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B. Kirsch, M.D., FAAN, FAASM to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. "We are honored to welcome Dr. Kirsch to the IHL-42X Clinical Advisory Board," stated Dr. Lou Barbato, Incannex Chief Medical Officer. "His extensive clinical experience and leadership within the sleep medicine community will be instrumental as we advance IHL-42X through late-stage development. With his additi

    6/24/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

    NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physiology Group in the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital.Ali Azarbarzin, Ph.D., Associate Professor of Medicine at Harvard Medical School and a lead

    6/3/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Financials

    Live finance-specific insights

    View All

    Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

    MELBOURNE, Australia, July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ:IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals. Cannabinoid IHL-42X: positive phase 2a clinical trial results in patients with obstructive sleep apnoea In June 2022, Incannex announced positive results from full analysis of its phase 2 clinical trial o

    7/27/22 7:55:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quarterly Activities Report and Appendix 4C Cash Flow Statement

    Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo study on the neuroprotective capability of IHL-216A with results being analysed to be released within 2-3 weeks treatment commences in the phase 2a clinical trial to assess psilocybin and specialised psychotherapy for the treatment of generalised anxiety disorder initiates a second clinical psychedelic therapy program in a leading-edge academic field of virtual reality (VR) exposure response therapy

    4/28/22 7:55:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care